Nov 22, 2012 (M2 PRESSWIRE via COMTEX) --
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4066 companies with "abnormal" market making, 3153 companies with positive Friction Factors and 2036 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Memsic Inc (NASDAQ:MEMS), Sequenom Inc (NASDAQ:SQNM), Vivus Inc (NASDAQ:VVUS), Oclaro Inc (NASDAQ:OCLR), China Digital Tv Holding Co Ltd (NYSE:STV), BG Medicine Inc (NASDAQ:BGMD). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Friction Factor is shown in the chart below:
Symbol Change Percent Buy Volume Buy %% Sell Volume Sell %% Net Volume Friction
MEMS $1.250 71.84% 886,376 51.65% 806,653 47.00% 79,723 638
SQNM $0.560 15.20% 3,785,318 55.77% 3,002,406 44.23% 782,912 13,981
VVUS $1.440 13.91% 8,708,784 52.39% 7,818,789 47.03% 889,995 6,181
OCLR $0.180 12.27% 712,914 67.74% 339,225 32.23% 373,689 20,761
STV $0.820 50.93% 1,126,108 32.35% 1,079,098 31.00% 47,010 573
BGMD $0.130 11.50% 789,397 64.87% 427,422 35.13% 361,975 27,844
Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.
For example, the chart above shows MEMS with a dollar gain Wednesday of $1.25000 and a Friction Factor of 638 shares. That means that it only took 638 more shares of buying than selling to move MEMS higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.
Memsic Inc (NASDAQ:MEMS) - MEMSIC, Inc. provides semiconductor sensor systems solutions based on micro electromechanical systems (MEMS) technology and mixed signal circuit design worldwide. It offers accelerometer products that are used to measure tilt, shock, vibration, and acceleration. These products have a range of applications in mobile phones; automotive safety systems consisting of airbags, rollover detection, electronic stability control, and navigation systems; and video projectors, as well as for business, industrial, and medical applications. The company also develops various types of sensor solutions, such as MEMS-based magnetic sensors that provide enhanced digital compass capabilities for mobile applications comprising cell phones and personal navigation devices. In addition, it provides wireless sensor technology and inertial MEMS sensors, and the eKo product line for environmental monitoring. The company sells its products to distributors, or to original equipment manufacturers and original design manufacturers. MEMSIC, Inc. was founded in 1999 and is headquartered in Andover, Massachusetts..
Sequenom Inc (NASDAQ:SQNM) - Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock. The company operates in two segments, Genetic Analysis and Molecular Diagnostics. The Genetic Analysis segment designs and markets MassARRAY system, a high performance nucleic acid analysis platform that comprises hardware, software applications, consumable chips, and reagents to measure genetic target material and variations. This segment offers its MassARRAY system for various DNA/RNA analysis applications, including single nucleotide polymorphism (SNP), genotyping detection of mutations, analysis of copy number variants, and other structural genome variations, as well as quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. It also provides iPLEX multiplexing assay, which permits multiplexed SNP analysis using a similar amount of reagents and chip surface area. The Genetic Analysis segment offers its products through direct sales, support personnel, and distribution partners to clinical research laboratories, bio-agriculture, bio-technology and pharmaceutical companies, academic institutions, and various government agencies worldwide. The Molecular Diagnostics segment researches, develops, and commercializes noninvasive molecular diagnostic tests for prenatal genetic disorders and diseases, womens health related disorders and diseases, age-related macular degeneration diagnostics, oncology, infectious diseases, and other diseases and disorders. This segment markets diagnostic technology for prenatal diagnostics under the trademark SEQureDx. The company was founded in 1994 and is headquartered in San Diego, California..
Vivus Inc (NASDAQ:VVUS) - VIVUS, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for underserved markets in the United States. It offers MUSE, a minimally invasive therapy for erectile dysfunction. The companys investigational product pipeline includes Qnexa that has completed Phase 3 clinical trials for obesity, and Phase 2 clinical trials for diabetes and obstructive sleep apnea; Avanafil, which is in phase 3 clinical trials to treat erectile dysfunction; and Luramist, which has completed phase 2 clinical trials for the treatment of hypoactive sexual desire disorder in women. It has a development, licensing, and supply agreement with Tanabe Seiyaku Co., Ltd. for the development and commercialization of Avanafil; and licensing agreements with Acrux and its subsidiary to develop and commercialize Luramist and Evamist in the United States. The company was founded in 1991 and is headquartered in Mountain View, California..
Oclaro Inc (NASDAQ:OCLR) - Oclaro, Inc. designs, manufactures, and markets optical components, modules, and subsystems that generate, detect, amplify, combine, and separate light signals in telecommunications networks. It offers telecom products, including tunable laser transmitters, fixed wavelength laser transmitters, lithium niobate modulators, receivers, transceivers, transponder modules, pump laser chips, and amplifiers. The companys telecom products also comprise wavelength management products consisting of switching and routing products, multiplexing and signal processing products, and micro-optics and integrated modules, as well as reconfigurable optical add drop multiplexers; and dispersion compensation management products. In addition, it provides advanced photonic solutions products, such as high powered laser diode products; VCSEL products; and thin film filter products. The company offers its telecom products to telecommunications systems and components vendors, as well as to customers in the data communications, military and aerospace industries; and advanced photonics solutions products to life-sciences, industrial printing, and consumer electronics components companies. It sells its products and services directly, as well as through international sales representatives and resellers primarily in the United States, Canada, Europe, and Asia. The company was formerly known as Bookham, Inc. and changed its name to Oclaro, Inc. in April 2009. Oclaro, Inc. was founded in 1988 and is headquartered in San Jose, California..
China Digital Tv Holding Co Ltd (NYSE:STV) - China Digital TV Holding Co., Ltd., through its subsidiaries, provides conditional access (CA) systems to digital television markets in the Peoples Republic of China. Its CA systems consist of smart cards and head-end software for television network operators, as well as terminal-end software for set-top box manufacturers, which enable digital television network operators to control the distribution of content and value-added services to their subscribers and block unauthorized access to their networks. The company licenses its set-top box design to set-top box manufacturers and sells advanced digital television application software, such as electronic program guides and subscriber management systems to digital television network operators. It also provides system integration services for television network operators. China Digital TV Holding Co., Ltd. sells its CA systems and digital television application software to television network operators, including cable, satellite, and terrestrial television network operators and enterprises that maintain private cable television networks within their facilities. As of December 31, 2009, it had installed CA systems at 244 digital television network operators in 27 provinces, autonomous regions, and centrally administered municipalities in the People's Republic of China. The company was founded in 2004 and is headquartered in Beijing, the Peoples Republic of China..
BG Medicine Inc (NASDAQ:BGMD) - BG Medicine, Inc., a life sciences company, engages in the discovery, development, and commercialization of molecular diagnostics based on biomarkers in the United States. Its product pipeline includes molecular diagnostics for cardiovascular diseases, such as congestive heart failure, coronary stenosis, and vulnerable plaque; cancers; and CNS disorders, including alzheimer's disease and multiple sclerosis, as well as for patients receiving Tysabri, a treatment that is associated with a side effect. The company also provides Avandia, a drug for the treatment of Type II diabetes; and Enbrel and Remicade, which are treatments indicated for autoimmune disorders, such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease, and other related conditions. In addition, it offers disease mechanisms, drug mechanisms, drug efficacy, drug toxicity, responder identification, and translational medicine services. The company has a research collaboration with Merck & Co. Inc. for the development and validation of a novel biomarker with potential application in the management of lipid disorders. The company was founded in 2000 as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in November 2004. BG Medicine, Inc. is headquartered in Waltham, Massachusetts..
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to firstname.lastname@example.org.